Telesis Bio(OTC) TBIO

Market Cap$78.40K

Since IPO (2021)-100%

5 Year-100%

1 Year-95%

1 Month-90%

$0.00

+0.00%

+0.00Today

Telesis Bio last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-08-14

Telesis Bio stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-9.09%	USD 0.00	2026-08-07
1 month	-90%	USD 0.01	2026-07-15
3 month	+0%	USD 0.00	2026-05-15
Year to date	-98%	USD 0.05	2025-12-31
1 year	-95.45%	USD 0.02	2025-08-14
3 year	-100%	USD 21.42	2023-08-15
5 year	-100%	USD 246.96	2021-08-13
Since inception	-100%	USD 333.00	2021-06-18

Telesis Bio Financials at a Glance

Market Cap

$78.40K

Revenue (TTM)

$13.53M

Net Income (TTM)

-$45.55M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-13.76 (Low)

Dividend

$0.00

Beta (Volatility)

-13.76 (Low)

Price

$0.00

Volume

427

Open

$0.00

Price

$0.00

Volume

427

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.15

Estimated Earnings Date

Aug 17, 2026

Dividend

$0.00

Beta (Volatility)

-13.76 (Low)

Price

$0.00

Volume

427

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.15

Estimated Earnings Date

Aug 17, 2026

TBIO News

Why Codex DNA Trounced the Market Today

Eric VolkmanDec 29, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Telesis Bio

Codex DNA, Inc. operates in the synthetic biology sector, focusing on the development, manufacturing, and sale of advanced instruments, reagents, and complementary services. The company primarily serves pharmaceutical firms and academic laboratories globally, while also catering to government institutions and contract research organizations.

Products and Services

BioXp system for transforming digital DNA sequences into synthetic DNA
BioXp portal for online DNA sequence design and assembly
Biofoundry Services for endpoint-ready BioXp products

Growth Outlook

Recent quarterly revenue of $1.566 million shows stability
Strong demand for synthetic biology solutions is expected to drive growth
Innovative product offerings position the company for future market expansion

Financial Highlights

Trailing twelve months revenue of $15.56 million indicates a solid revenue base
Gross profit margin of 64.43% in Q3 2024 reflects operational efficiency
Current ratio of 3.71 suggests strong liquidity and financial health

Codex DNA, Inc. has established itself as a key player in the synthetic biology industry, leveraging innovative technologies to meet the growing needs of its diverse customer base. The company's flagship products, including the BioXp system and portal, facilitate the rapid development of synthetic DNA, which is crucial for various applications in research and pharmaceuticals. The growth outlook remains positive, driven by increasing demand for synthetic biology solutions and the company's commitment to innovation. Recent financial performance highlights a stable revenue stream and strong gross profit margins, indicating effective cost management and operational efficiency. With a robust current ratio, Codex DNA is well-positioned to navigate future challenges and capitalize on emerging opportunities in the synthetic biology market.

AI Generated • Jul 31, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

CEO

Eric Esser

Website

telesisbio.com

Headquarters

San Diego, CA 92121-2993, US

TBIO Financials

Key Financial Metrics (TTM)

Gross Margin

61.62%

Operating Margin

-169.18%

Net Income Margin

-173.49%

Return on Equity

-125.42%

Return on Capital

-72.81%

Return on Assets

-67.78%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$78.40K

Shares Outstanding

78.39M

Volume

427

Avg. Volume

548.476

Financials (TTM)

Gross Profit

$4.58M

Operating Income

-$30.56M

EBITDA

-$38.48M

Operating Cash Flow

-$22.85M

Capital Expenditure

-$890.00K

Free Cash Flow

-$23.74M

Cash & ST Invst.

$4.51M

Total Debt

$16.29M

Telesis Bio Performance Analysis

Telesis Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 11,043,000	N/A
2022	2022-12-31	USD 27,435,000	148.4%
2023	2023-12-31	USD 27,509,000	0.3%

Telesis Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2023-12-31	25.4%
Q1	2024-03-31	-50.7%
Q2	2024-06-30	-54.9%
Q3	2024-09-30	1.0%

Telesis Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -23.92	N/A
2022	2022-12-31	USD -29.61	23.8%
2023	2023-12-31	USD -29.56	-0.2%

Telesis Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2023-12-31	-68.6%
Q1	2024-03-31	50.8%
Q2	2024-06-30	-2527.6%
Q3	2024-09-30	49.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2024YOY CHG

Revenue

$1.57M

-71.9%

Gross Profit

$1.01M

-66.3%

Gross Margin

64.43%

N/A

Market Cap

$78.40K

N/A

Market Cap/Employee

$2.01K

N/A

Employees

N/A

Net Income

-$6.64M

+37.5%

EBITDA

-$4.68M

+48.7%

Quarterly Fundamentals

Name

Q3 2024YOY CHG

Total Cash

$4.51M

-89.1%

Total Debt

$16.29M

-67.4%

Accounts Receivable

$1.26M

-76.4%

Inventory

$1.10M

-74.3%

Long Term Debt

$14.09M

-57.3%

Short Term Debt

$4.41M

-74.0%

Return on Assets

-67.78%

N/A

Return on Invested Capital

-74.79%

N/A

Free Cash Flow

-$7.01M

-17.1%

Operating Cash Flow

-$6.96M

-18.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PPJEPPJ Healthcare Enterprises, Inc.

PPJEPPJ Healthcare Enterprises, Inc.$0.00+0.00%

CATV4Cable TV International, Inc.

CATV4Cable TV International, Inc.$0.00+0.00%

CHMEChina Medicine Corp.

CHMEChina Medicine Corp.$0.04+0.00%

MAHNMid-Atlantic Home Health Network, Inc.

MAHNMid-Atlantic Home Health Network, Inc.$0.11+0.00%

ESMCEscalon Medical Corp.

ESMCEscalon Medical Corp.$0.20+17.65%

CYDXCYduct Diagnostics, Inc.

CYDXCYduct Diagnostics, Inc.$2.08+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NUNu Holdings

NUNu Holdings$15.23+0.09%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.76+0.01%

ONDSOndas

ONDSOndas$9.24+0.04%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$140.00-0.01%

INTCIntel

INTCIntel$102.50-0.02%

NVDANvidia

NVDANvidia$225.16-0.00%

NOKNokia

NOKNokia$10.76+0.02%

Questions About TBIO

What is the current price of Telesis Bio?

Telesis Bio is trading at $0.00 per share.

What is the 52-week range for Telesis Bio?

Over the past 52 weeks, Telesis Bio has traded between $0.00 and $0.15.

How much debt does Telesis Bio have?

As of the most recent reporting period, Telesis Bio reported total debt of $16.29M.

How much cash does Telesis Bio have on hand?

Telesis Bio reported $3.82M in cash and cash equivalents in its most recent financial results.

What is Telesis Bio’s dividend yield?

Telesis Bio does not currently have a dividend yield.

Telesis Bio(OTC) TBIO

Telesis Bio Financials at a Glance

TBIO News

Why Codex DNA Trounced the Market Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Telesis Bio

TBIO Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Telesis Bio Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About TBIO

What is the current price of Telesis Bio?

What is the 52-week range for Telesis Bio?

How much debt does Telesis Bio have?

How much cash does Telesis Bio have on hand?

What is Telesis Bio’s dividend yield?

Premium Investing Services